Clinical stage biopharmaceutical company Carisma Therapeutics Inc on Tuesday announced an expansion of its in vivo CAR-M collaboration with Moderna Inc (Nasdaq:MRNA) to include the development of two therapies for autoimmune diseases.
Building on their successful pre-clinical work in oncology, the companies will leverage their respective technologies to develop novel in vivo macrophage engineering approaches for two nominated autoimmune disease targets.
Carisma will receive research funding and milestone payments, as well as royalties on any commercialised products.
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment